Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
- DOI
- 10.1111/apt.17242
- Published
- 2022-10-20
- Container
- Aliment Pharmacol Ther
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/apt.17242,
title = {Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.},
author = {Peyrin-Biroulet L and Ghosh S and Lee SD and Lee WJ and Griffith J and Wallace K and Berg S and Liao X and Panes J and Loftus EV and Louis E.},
year = {2023},
journal = {Aliment Pharmacol Ther},
doi = {10.1111/apt.17242},
url = {https://doi.org/10.1111/apt.17242}
}RIS
TY - JOUR TI - Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. AU - Peyrin-Biroulet L AU - Ghosh S AU - Lee SD AU - Lee WJ AU - Griffith J AU - Wallace K AU - Berg S AU - Liao X AU - Panes J AU - Loftus EV AU - Louis E. PY - 2023 JO - Aliment Pharmacol Ther DO - 10.1111/apt.17242 UR - https://doi.org/10.1111/apt.17242 ER -
APA
L, P., S, G., SD, L., WJ, L., J, G., K, W., S, B., X, L., J, P., EV, L., & E., L. (2023). Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.. Aliment Pharmacol Ther. https://doi.org/10.1111/apt.17242
Source records
- europe-pmc · retrieved 2026-09-25T13:34:44.900Z
- hal · retrieved 2026-09-25T13:34:44.947Z